Patient access has become a commercial challenge that extends far beyond traditional market access. In this MM+M article, Dane Schroeder explores why launch planning, payer strategy, affordability, and cross-functional collaboration must come together earlier to improve real-world access to therapies. Learn why leading pharmaceutical organizations are treating access as a commercial imperative, not simply a market access function.